Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes

Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of major adverse cardiovascular (CV) events and hospitalization for heart failure (HF) in patients with type 2 diabetes (T2D). Using CV MRI (CMR) and (31)P-MRS in a longitudinal cohort study, we aimed to investigate the effects of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Thirunavukarasu, Sharmaine, Jex, Nicholas, Chowdhary, Amrit, Hassan, Imtiaz Ul, Straw, Sam, Craven, Thomas P., Gorecka, Miroslawa, Broadbent, David, Swoboda, Peter, Witte, Klaus K., Cubbon, Richard M., Xue, Hui, Kellman, Peter, Greenwood, John P., Plein, Sven, Levelt, Eylem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2021
Materias:
Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660983/
https://www.ncbi.nlm.nih.gov/pubmed/34610982
http://dx.doi.org/10.2337/db21-0270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660983/
https://www.ncbi.nlm.nih.gov/pubmed/34610982
http://dx.doi.org/10.2337/db21-0270

Ejemplares similares